Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
作者： Vladislava Simkova , Peter Radermacher , Eberhard Barth
DOI: 10.1186/CC5924
关键词:
摘要: Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with surgery. Their effects on energy metabolism visceral organ function not well studied, however, particularly in comparison their 'competitors' daily practice (that is, catecholamines).
biomedcentral.com
springer.com
paperity.org参考文章(17)
Sezai A, Orime Y, Sezai Y, Obana M, Shiono M, Yamada H, Tsukamoto S, Hata H, Yagi S, Kimura S, Ohmiya S, Post-operative effects of olprinone after coronary artery bypass grafting. Annals of Thoracic and Cardiovascular Surgery. ,vol. 4, pp. 340- 346 ,(1998)
Xavier Leverve, Hyperglycemia and oxidative stress: complex relationships with attractive prospects Intensive Care Medicine. ,vol. 29, pp. 511- 514 ,(2003) , 10.1007/S00134-002-1629-3
Ilse Vanhorebeek, Catherine Ingels, Greet Van den Berghe, Intensive insulin therapy in high-risk cardiac surgery patients: evidence from the Leuven randomized study. Seminars in Thoracic and Cardiovascular Surgery. ,vol. 18, pp. 309- 316 ,(2006) , 10.1053/J.SEMTCVS.2006.05.001
Hartmut Kern, Torsten Schröder, Marco Kaulfuss, Michael Martin, Wolfgang J. Kox, Claudia D. Spies, Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. Critical Care Medicine. ,vol. 29, pp. 1519- 1525 ,(2001) , 10.1097/00003246-200108000-00004
X. M. Leverve, From tissue perfusion to metabolic marker: assessing organ competition and co-operation in critically ill patients? Intensive Care Medicine. ,vol. 25, pp. 890- 892 ,(1999) , 10.1007/S001340050976
Christina Routsi, Elisabeth Stamataki, Seraphim Nanas, Christina Psachoulia, Anastasios Stathopoulos, Apostolos Koroneos, Maria Zervou, Gerard Jullien, Charis Roussos, INCREASED LEVELS OF SERUM S100B PROTEIN IN CRITICALLY ILL PATIENTS WITHOUT BRAIN INJURY Shock. ,vol. 26, pp. 20- 24 ,(2008) , 10.1097/01.SHK.0000209546.06801.D7
P. Siostrzonek, M. Koreny, G. Delle-Karth, M. Haumer, J. Koller-Strametz, G. Heinz, Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiologica Scandinavica. ,vol. 44, pp. 403- 409 ,(2000) , 10.1034/J.1399-6576.2000.440408.X
Ronald J. Trof, Francesco Di Maggio, Jan Leemreis, A.B. Johan Groeneveld, Biomarkers of acute renal injury and renal failure. Shock. ,vol. 26, pp. 245- 253 ,(2006) , 10.1097/01.SHK.0000225415.5969694.CE
Thomas Mollhoff, Heinz M. Loick, Hugo Van Aken, Christoph Schmidt, Norbert Rolf, Tonny D. T. Tjan, Boulos Asfour, Elmar Berendes, Milrinone Modulates Endotoxemia, Systemic Inflammation, and Subsequent Acute Phase Response after Cardiopulmonary Bypass (CPB) Anesthesiology. ,vol. 90, pp. 72- 80 ,(1999) , 10.1097/00000542-199901000-00012
Eberhard Barth, Gerd Albuszies, Katja Baumgart, Martin Matejovic, Ulrich Wachter, Josef Vogt, Peter Radermacher, Enrico Calzia, Glucose metabolism and catecholamines. Critical Care Medicine. ,vol. 35, ,(2007) , 10.1097/01.CCM.0000278047.06965.20